<p>週一，Summit 治療股價上漲了 0.8%。該公司股價最高達到 22.17 美元，最後交易價為 21.39 美元。交易中約有 592,087 股換手，較平均每日成交量 3,717,354 股下降了 84%。該股上一個收盤價為 21.21 美元。</p>
<p>獲取 <strong>Summit 治療</strong> 警報：</p>
<h2>分析師評級</h2>
<ul>
<li>Summit 治療因試驗結果大漲：是時候買入了嗎？</li>
</ul>
<p>一些研究分析師最近對 SMMT 股票發表了意見。HC Wainwright 在 10 月 4 日星期五的報告中重申了對 Summit 治療股票的 “買入” 評級，並設定了 45.00 美元的目標價。Stifel Nicolaus 在 9 月 25 日星期三的報告中將他們對 Summit 治療股票的目標價從 25.00 美元上調至 40.00 美元，並給予了 “買入” 評級。最後，花旗集團在 9 月 27 日星期五的報告中將對 Summit 治療股票的評級從 “買入” 調降至 “中性”，並將目標價從 19.00 美元上調至 23.00 美元。</p>
<p>獲取我們對 Summit 治療的最新股票報告</p>
<h2>Summit 治療股價下跌 3.5%</h2>
<p>該公司的五十日移動平均線為 18.34 美元，兩百日移動平均線為 10.82 美元。</p>
<p>Summit 治療（NASDAQ:SMMT - 獲取免費報告）最近公佈了其截至 8 月 6 日星期二的財報。該公司本季度每股虧損 0.05 美元，超過了每股虧損 0.06 美元的共識預期 0.01 美元。分析師平均預計，Summit 治療公司本財年每股盈利為-0.27 美元。</p>
<h2>Summit 治療的機構交易</h2>
<p>對該股票進行了買賣的對沖基金和其他機構投資者。Griffin Asset Management Inc.在第三季度以 148.4 萬美元的價格獲得了 Summit 治療的新股份。Millennium Management LLC 在第二季度以約 1515.4 萬美元的價格購入了 Summit 治療的新頭寸。Mirae Asset Global Investments Co. Ltd.在第一季度將其對 Summit 治療的持股比例提高了 131.3%。Mirae Asset Global Investments Co. Ltd.現在擁有該公司股票的 40,476 股，價值 168,000 美元，較上一季度增持了 22,977 股。SG Americas Securities LLC 在第三季度以約 71.7 萬美元的價格購入了 Summit 治療的新頭寸。最後，Squarepoint Ops LLC 在第二季度將其對 Summit 治療的持股比例提高了 192.2%。Squarepoint Ops LLC 現在擁有該公司股票的 86,064 股，價值 671,000 美元，較上一季度增持了 56,614 股。目前有 4.61% 的股份由機構投資者和對沖基金持有。</p>
<h2>Summit 治療公司簡介（獲取免費報告）</h2>
<p>Summit 治療公司是一家生物製藥公司，專注於在美國和英國發現、開發和商業化對患者、醫生、護理人員和社會友好的藥物療法。該公司的主要開發候選藥物是 Ivonescimab，一種通過 PD-1 阻斷和抗血管生成作用進行免疫療法的雙特異性抗體；抗感染組合包括 SMT-738，一種用於治療多藥耐藥感染的新型精準抗生素，主要包括碳青黴烯耐藥腸桿菌感染。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五隻股票比 Summit 治療更好</li>
<li>如何計算投資回報率（ROI）</li>
<li>分析師預測網絡安全股票將在聖誕節前創新高</li>
<li>CD 計算器：定期存款計算器</li>
<li>核能達到臨界質量：現在關注的熱門股票</li>
<li>股票中的跳空意味着什麼？如何把握這個跳空</li>
<li>兩家能源公司因獲得十億美元的能源部貸款承諾而大漲</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 查爾斯·佩恩希望您為第四季度做好準備（來自不可阻擋的繁榮）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTU4"/></p>
<h2>您現在是否應該投資 1,000 美元購買 Summit 治療股票？</h2>
<p>在考慮購買 Summit 治療股票之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高、表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Summit 治療並不在名單上。</p>
<p>儘管 Summit 治療目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Summit治療

<p>Summit 治療（NASDAQ:SMMT）看到其股價上漲了 0.8%，達到 0.39 美元，成交量為 592,087 股，遠低於其平均交易量。分析師對此持有不同觀點：HC Wainwright 維持 “買入” 評級，目標價為 0.00 美元，而花旗集團將其降級為 “中性”。該公司報告的每股收益為-0.05 美元，超過了預期。機構投資者增加了持股比例，持有該股的 4.61%。Summit 專注於開發多藥耐藥感染和免疫療法的治療方案</p>

<p>Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report)'s share price was up 0.8% on Monday . The company traded as high as $22.17 and last traded at $21.39. Approximately 592,087 shares changed hands during trading, a decline of 84% from the average daily volume of 3,717,354 shares. The stock had previously closed at $21.21.</p>
<div class="lb-trans"><p>週一，Summit 治療股價上漲了 0.8%。該公司股價最高達到 22.17 美元，最後交易價為 21.39 美元。交易中約有 592,087 股換手，較平均每日成交量 3,717,354 股下降了 84%。該股上一個收盤價為 21.21 美元。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Summit 治療</strong> 警報：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<ul>
<li>Summit Therapeutics Surges on Trial Results: Time to Buy?</li>
</ul>
<div class="lb-trans"><h2>分析師評級</h2>
<ul>
<li>Summit 治療因試驗結果大漲：是時候買入了嗎？</li>
</ul>
</div><p>A number of research analysts have recently weighed in on SMMT shares. HC Wainwright restated a &#34;buy&#34; rating and set a $45.00 price target on shares of Summit Therapeutics in a report on Friday, October 4th. Stifel Nicolaus lifted their target price on shares of Summit Therapeutics from $25.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 25th. Finally, Citigroup downgraded shares of Summit Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lifted their target price for the stock from $19.00 to $23.00 in a report on Friday, September 27th.</p>
<div class="lb-trans"><p>一些研究分析師最近對 SMMT 股票發表了意見。HC Wainwright 在 10 月 4 日星期五的報告中重申了對 Summit 治療股票的 “買入” 評級，並設定了 45.00 美元的目標價。Stifel Nicolaus 在 9 月 25 日星期三的報告中將他們對 Summit 治療股票的目標價從 25.00 美元上調至 40.00 美元，並給予了 “買入” 評級。最後，花旗集團在 9 月 27 日星期五的報告中將對 Summit 治療股票的評級從 “買入” 調降至 “中性”，並將目標價從 19.00 美元上調至 23.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Summit Therapeutics</strong></p>
<div class="lb-trans"><p>獲取我們對 Summit 治療的最新股票報告</p>
</div><h2>Summit Therapeutics Stock Down 3.5 %</h2>
<div class="lb-trans"><h2>Summit 治療股價下跌 3.5%</h2>
</div><p>The firm's fifty day moving average is $18.34 and its 200 day moving average is $10.82.</p>
<div class="lb-trans"><p>該公司的五十日移動平均線為 18.34 美元，兩百日移動平均線為 10.82 美元。</p>
</div><p>Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect that Summit Therapeutics Inc. will post -0.27 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Summit 治療（NASDAQ:SMMT - 獲取免費報告）最近公佈了其截至 8 月 6 日星期二的財報。該公司本季度每股虧損 0.05 美元，超過了每股虧損 0.06 美元的共識預期 0.01 美元。分析師平均預計，Summit 治療公司本財年每股盈利為-0.27 美元。</p>
</div><h2>Institutional Trading of Summit Therapeutics</h2>
<div class="lb-trans"><h2>Summit 治療的機構交易</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the stock. Griffin Asset Management Inc. acquired a new stake in Summit Therapeutics in the 3rd quarter worth $1,484,000. Millennium Management LLC bought a new position in shares of Summit Therapeutics in the second quarter worth about $15,154,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Summit Therapeutics by 131.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,476 shares of the company's stock worth $168,000 after buying an additional 22,977 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Summit Therapeutics during the third quarter worth approximately $717,000. Finally, Squarepoint Ops LLC raised its stake in shares of Summit Therapeutics by 192.2% during the second quarter. Squarepoint Ops LLC now owns 86,064 shares of the company's stock worth $671,000 after buying an additional 56,614 shares during the last quarter. 4.61% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>對該股票進行了買賣的對沖基金和其他機構投資者。Griffin Asset Management Inc.在第三季度以 148.4 萬美元的價格獲得了 Summit 治療的新股份。Millennium Management LLC 在第二季度以約 1515.4 萬美元的價格購入了 Summit 治療的新頭寸。Mirae Asset Global Investments Co. Ltd.在第一季度將其對 Summit 治療的持股比例提高了 131.3%。Mirae Asset Global Investments Co. Ltd.現在擁有該公司股票的 40,476 股，價值 168,000 美元，較上一季度增持了 22,977 股。SG Americas Securities LLC 在第三季度以約 71.7 萬美元的價格購入了 Summit 治療的新頭寸。最後，Squarepoint Ops LLC 在第二季度將其對 Summit 治療的持股比例提高了 192.2%。Squarepoint Ops LLC 現在擁有該公司股票的 86,064 股，價值 671,000 美元，較上一季度增持了 56,614 股。目前有 4.61% 的股份由機構投資者和對沖基金持有。</p>
</div><h2>Summit Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Summit 治療公司簡介（獲取免費報告）</h2>
</div><p>Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.</p>
<div class="lb-trans"><p>Summit 治療公司是一家生物製藥公司，專注於在美國和英國發現、開發和商業化對患者、醫生、護理人員和社會友好的藥物療法。該公司的主要開發候選藥物是 Ivonescimab，一種通過 PD-1 阻斷和抗血管生成作用進行免疫療法的雙特異性抗體；抗感染組合包括 SMT-738，一種用於治療多藥耐藥感染的新型精準抗生素，主要包括碳青黴烯耐藥腸桿菌感染。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Summit Therapeutics</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>Analysts Predict New Highs for Cybersecurity Stock by Christmas</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments</li>
</ul>
<div class="lb-trans"><h2>進一步閲讀</h2>
<ul>
<li>我們喜歡的五隻股票比 Summit 治療更好</li>
<li>如何計算投資回報率（ROI）</li>
<li>分析師預測網絡安全股票將在聖誕節前創新高</li>
<li>CD 計算器：定期存款計算器</li>
<li>核能達到臨界質量：現在關注的熱門股票</li>
<li>股票中的跳空意味着什麼？如何把握這個跳空</li>
<li>兩家能源公司因獲得十億美元的能源部貸款承諾而大漲</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Charles Payne Wants You Prepared for Q4 (From Unstoppable Prosperity)(Ad)</p>
<div class="lb-trans"><p>→ 查爾斯·佩恩希望您為第四季度做好準備（來自不可阻擋的繁榮）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTU4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9958&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Summit Therapeutics right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買 Summit 治療股票？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Summit 治療股票之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高、表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Summit 治療並不在名單上。</p>
</div><p>While Summit Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Summit 治療目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Summit 治療公司（納斯達克代碼：SMMT）股價上漲 0.8% - 事件詳情如下